Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone 5 mg for endometriosis over two 24-week treatment cycles
2020-004302-63Phase 3Terminated
- Sponsor
- Litaphar
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mifepristone in endometriosis, sponsored by Litaphar. Primary endpoint: Histological appearance of the endometrium. Started Nov 2020; status: terminated.
02
Drugs
mifepristone
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2020-004302-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004302-63.